Schneeweiss S - Search Results

1

Characteristics of study design and elements that may contribute to the success of electronic safety monitoring systems.

Bell C, Chakravarty A, Gruber S, Heckbert SR, Levenson M, Martin D, Nelson JC, Pinheiro S, Psaty BM, Reich CG, Schneeweiss S, Shoaibi A, Toh S, Walker AM. Bell C, et al. Among authors: schneeweiss s. Pharmacoepidemiol Drug Saf. 2014 Nov;23(11):1223-5. doi: 10.1002/pds.3712. Epub 2014 Sep 29. Pharmacoepidemiol Drug Saf. 2014. PMID: 25263307 No abstract available.

2

Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.

Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB. Schneeweiss S, et al. N Engl J Med. 2002 Mar 14;346(11):822-9. doi: 10.1056/NEJMsa003087. N Engl J Med. 2002. PMID: 11893794 Free article.

3

Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.

Schneeweiss S, Soumerai SB, Glynn RJ, Maclure M, Dormuth C, Walker AM. Schneeweiss S, et al. CMAJ. 2002 Mar 19;166(6):737-45. CMAJ. 2002. PMID: 11944760 Free PMC article.

4

Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers.

Schneeweiss S, Soumerai SB, Maclure M, Dormuth C, Walker AM, Glynn RJ. Schneeweiss S, et al. Clin Pharmacol Ther. 2003 Oct;74(4):388-400. doi: 10.1016/S0009-9236(03)00227-3. Clin Pharmacol Ther. 2003. PMID: 14534526

5

Aprotinin during coronary-artery bypass grafting and risk of death.

Schneeweiss S, Seeger JD, Landon J, Walker AM. Schneeweiss S, et al. N Engl J Med. 2008 Feb 21;358(8):771-83. doi: 10.1056/NEJMoa0707571. N Engl J Med. 2008. PMID: 18287600 Free article.

6

Effect of aprotinin on renal dysfunction.

Schneeweiss S, Walker AM, Seeger JD. Schneeweiss S, et al. Lancet. 2008 Jul 5;372(9632):26; author reply 26-7. doi: 10.1016/S0140-6736(08)60980-0. Lancet. 2008. PMID: 18603149 No abstract available.

7

A basic study design for expedited safety signal evaluation based on electronic healthcare data.

Schneeweiss S. Schneeweiss S. Pharmacoepidemiol Drug Saf. 2010 Aug;19(8):858-68. doi: 10.1002/pds.1926. Pharmacoepidemiol Drug Saf. 2010. PMID: 20681003 Free PMC article.

8

An event-based approach for comparing the performance of methods for prospective medical product monitoring.

Gagne JJ, Walker AM, Glynn RJ, Rassen JA, Schneeweiss S. Gagne JJ, et al. Among authors: schneeweiss s. Pharmacoepidemiol Drug Saf. 2012 Jun;21(6):631-9. doi: 10.1002/pds.2347. Epub 2012 Jan 4. Pharmacoepidemiol Drug Saf. 2012. PMID: 22223544 Free PMC article.

9

The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction.

Platt R, Carnahan RM, Brown JS, Chrischilles E, Curtis LH, Hennessy S, Nelson JC, Racoosin JA, Robb M, Schneeweiss S, Toh S, Weiner MG. Platt R, et al. Among authors: schneeweiss s. Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:1-8. doi: 10.1002/pds.2343. Pharmacoepidemiol Drug Saf. 2012. PMID: 22262586

10

Design considerations in an active medical product safety monitoring system.

Gagne JJ, Fireman B, Ryan PB, Maclure M, Gerhard T, Toh S, Rassen JA, Nelson JC, Schneeweiss S. Gagne JJ, et al. Among authors: schneeweiss s. Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:32-40. doi: 10.1002/pds.2316. Pharmacoepidemiol Drug Saf. 2012. PMID: 22262591

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

610 results

Search Page